Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Support
This activity is supported by an educational grant from MorphoSys.
Community Practice Connections™: Illustrated Case Discussions: Practical Approaches to Treating Relapsed/Refractory DLBCL in 2021
Release Date: August 31, 2021
Expiration Date: August 31, 2022
Diffuse large B-cell lymphoma (DLBCL) is one of the most common forms of non-Hodgkin lymphoma (NHL); it accounts for approximately 30% of cases. Treatment options for patients with relapsed and/or refractory DLBCL are evolving rapidly, with the recent addition of several new active agents to the armamentarium, and numerous other promising therapies in late-stage clinical development. Clinicians need to understand the evidence supporting these new options, and how to individualize and sequence treatments in order to optimize outcomes for their patients with DLBCL.
This Community Practice Connection™ program provides an in-depth review of some of the key highlights from the “Illustrated Case Discussions: Practical Approaches to Treating Relapsed/Refractory DLBCL in 2021” satellite symposium, held in June 2021. This unique and engaging multimedia activity is directed towards the community-based clinician and focuses on the practical aspects of managing patients with DLBCL; it puts recent clinical trial data into clinical context. The program is designed for those who did not attend the live meeting and to help reinforce learnings for those who did.
Acknowledgement of Commercial SupportThis activity is supported by an educational grant from MorphoSys.
Instructions for This Activity and Receiving Credit
You may immediately download your certificate.
Upon successful completion of this activity, you should be better prepared to:
- Identify unmet clinical needs among patients with DLBCL in the context of ongoing clinical trials to address these gaps in multiple lines of care
- Outline key factors to stratify risk and customize treatment approaches for patients with relapsed DLBCL subsequent to frontline therapy
- Evaluate how recent trial evidence impacts clinical decision-making regarding evolving treatment options for patients with relapsed and relapsed/refractory forms of DLBCL
- Illustrate how emerging data sets and patient-specific information can be leveraged to optimize decision-making among transplant-ineligible patients with relapsed DLBCL
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.
Associate Professor of Medicine and Oncology
Consultant, Division of Hematology, Department of Internal Medicine
Disclosures: Grant research support: Celgene Corporation/Bristol Myers Squibb, MorphoSys, NanoStrings Technologies, Hoffmann-La Roche; Consultant: Celgene Corporation/Bristol Myers Squibb, MorphoSys, Ryvu Therapeutics, Kite Pharma, Kymera Therapeutics, Curis, Seattle Genetics, Hoffmann-La Roche, Blueprint Medicines Corporation, Incyte Corporation
Division head ad interim, Division of Cancer Medicine
Chair & Professor, Department of Lymphoma/Myeloma
The University of Texas MD Anderson Cancer Center
Disclosures: Consultant: AbbVie, Bayer Healthcare, BeiGene, Celgene Corporation, Denovo, Biopharma, Genentech/F. Hoffmann-La Roche (unpaid), Gilead Sciences, Karyopharm, MEI Pharmaceuticals, Pharmacyclics/Janssen Pharmaceutica, Spectrum Pharmaceuticals; Other: Contracted Research: AbbVie, Acerta Pharma, Celgene Corporation, Genentech/Hoffmann-La Roche, Gilead Sciences, Janssen Pharmaceutica, Millennium Pharmaceuticals/Takeda Pharmaceuticals, Pharmacyclics, TG Therapeutics, Burroughs Wellcome Fund, Cancer Prevention and Research Institute of Texas, Eastern Cooperative Oncology Group, National Cancer Institute, V Foundation
Physician-in-chief, Hackensack Meridian Health Oncology Care Transformation Service
Chairman & chief physician officer, John Theurer Cancer Center
Lydia Pfund chair for lymphoma and academic chairman oncology, Hackensack Meridian School of Medicine at Seton Hall University
Professor of medicine, Georgetown University
Disclosures: Grant research support: Primary Investigator: Acerta Pharma, AstraZeneca, Celgene Corporation, Constellation Pharmaceuticals, Genentech/Hoffmann-La Roche, Infinity Pharmaceuticals, Infinity Pharmaceuticals/Verastem Oncology, Janssen Pharmaceutica, Karyopharm, Kite Pharma, Pharmacyclics; Shareholder: COTA Healthcare; Other: Honoraria: Kite Pharma, Gilead Sciences, Celgene Corporation, AstraZeneca, Xcenda; Advisory: AstraZeneca, COTA Healthcare, Elsevier’s PracticeUpdate - Oncology, Gilead Sciences, Janssen Pharmaceutica, Kite Pharma
Professor of clinical internal medicine & director of the Lymphoma Program
Division of Hematology, Department of Internal Medicine
The James Cancer Hospital and Solove Research Institute at The Ohio State University
The Ohio State University Wexner Medical Center
Disclosures: Grant research support: Pharmacyclics, Bristol Myers Squibb, Merck & Co, Novartis Pharmaceuticals Corporation; Consultant: Pharmacyclics, Janssen Pharmaceutica, MorphoSys, Celgene Corporation, BeiGene, Kite Pharma, Karyopharm, ADC Therapeutics, Seattle Genetics
Chair, Lymphoma Tumour Group, BC Cancer
Clinical professor of medicine, Division of Medical Oncology, University of British Columbia
Associate editor, Blood
Disclosures: Grant research support: Teva Pharmaceuticals, Hoffmann-La Roche (Genentech); Consultant: AbbVie, Acerta Pharma, Amgen, Apobiologix, AstraZeneca, Celgene Corporation, Gilead Sciences, Incyte Corporation, Janssen Pharmaceutica, Kite Pharma, Karyopharm, Lundbeck, Merck & Co, MorphoSys, Hoffmann-La Roche/Genentech, Teva Pharmaceuticals, Takeda Pharmaceuticals, and TG Therapeutics
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Login or Register to Start Activity
Please use the form below to Register or Log In to begin Activity.